相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses
John P. A. Ioannidis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
The Cross-Validated Adaptive Signature Design
Boris Freidlin et al.
CLINICAL CANCER RESEARCH (2010)
Sources of Bias in Specimens for Research About Molecular Markers for Cancer
David F. Ransohoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Clinical Trials With Biomarkers: Design Issues
Boris Freidlin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Design and Analysis Considerations in Clinical Trials With a Sensitive Subpopulation
Yan D. Zhao et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2010)
A Comparison of Phase II Study Strategies
Sally Hunsberger et al.
CLINICAL CANCER RESEARCH (2009)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Optimal Cost-Effective Designs of Phase II Proof of Concept Trials and Associated Go-No Go Decisions
Cong Chen et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2009)
Monitoring and Predicting Response to Therapy with F-18-FDG PET in Colorectal Cancer: A Systematic Review
Lioe-Fee de Geus-Oei et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology
Werner Brannath et al.
STATISTICS IN MEDICINE (2009)
Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug Development
Cong Chen et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2009)
Hypothesis Testing in a Confirmatory Phase III Trial With a Possible Subset Effect
Cong Chen et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2009)
The Use of Genomics in Clinical Trial Design
Richard Simon
CLINICAL CANCER RESEARCH (2008)
Interim futility analysis with intermediate endpoints
Bryan Goldman et al.
CLINICAL TRIALS (2008)
Clinical oncology: Onward and upward
George P. Canellos
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Detection of mutations in EGFR in circulating lung-cancer cells
Shyamala Maheswaran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 Randomized controlled trials of first-line chemotherapy
Patricia A. Tang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adaptive, group sequential and decision theoretic approaches to sample size determination
Cyrus R. Mehta et al.
STATISTICS IN MEDICINE (2006)
Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim:: General concepts
Frank Bretz et al.
BIOMETRICAL JOURNAL (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Bayesian clinical trials
DA Berry
NATURE REVIEWS DRUG DISCOVERY (2006)
Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
B Freidlin et al.
CLINICAL CANCER RESEARCH (2005)
Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development
L Yan et al.
BIOTECHNIQUES (2005)
Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis
DA Berry
CLINICAL TRIALS (2005)
PET for response assessment in oncology: radiotherapy and chemotherapy
WA Weber
BRITISH JOURNAL OF RADIOLOGY (2005)
Clonogenic assay with established human tumour xenografts:: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery
HH Fiebig et al.
EUROPEAN JOURNAL OF CANCER (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Cancer Modeling in the modern era: Progress and challenges
T Van Dyke et al.
CELL (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
